BGIM
PRTK

Brandywine Global Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Brandywine Global Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-495
Closed -$13K – 1042
2014
Q3 		$13K Sell
495
-5
-1% -$131 ﹤0.01% 897
2014
Q2 		$12K Buy
+500
New +$16.3K ﹤0.01% 903

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brandywine Global Investment Management's PRTK Position: Q4 2014 in Review

Brandywine Global Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2014, closing a stake of 495 shares — an estimated $13K sold.

Brandywine Global Investment Management first reported a position in PRTK in Q2 2014 and held it in 2 quarters. The position peaked at $13K in Q3 2014. 37 funds tracked by Wall St. Rank hold PRTK as of Q4 2014.

  • Brandywine Global Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Brandywine Global Investment Management sold 495 Paratek Pharmaceuticals, Inc. shares in Q4 2014, an estimated $13K.
  • Brandywine Global Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Brandywine Global Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $13K in Q3 2014.
  • 37 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2014.

Based on Brandywine Global Investment Management's 13F filing for Q4 2014, filed 17 Feb 2015.